デジタルパソロジーの世界市場：スキャナー、ソフトウェア、通信システム、ストレージシステム...市場調査レポートについてご紹介

1 Introduction (Page No. – 14)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 17)
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.2.1 Key Data From Primary Sources
2.2.2.2 Key Insights From Primary Sources
2.2.2.3 Key Industry Insights
2.3 Market Size Estimation Methodology
2.4 Research Design
2.5 Market Data Validation and Triangulation
2.6 Assumptions for the Study

3 Executive Summary (Page No. – 26)
3.1 Introduction
3.2 Conclusion

4 Premium Insights (Page No. – 31)
4.1 Overview of the Market
4.2 Geographic Analysis of the Market
4.3 Market, By Type
4.4 Market, By End User
4.5 Market, By Application
4.6 Geographic Snapshot of the Market

5 Market Overview (Page No. – 35)
5.1 Introduction
5.2 Market Segmentation
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Prevalence of Cancer
5.3.1.2 Increasing Adoption of Digital Pathology to Enhance Lab Efficiency
5.3.1.3 Growing Application of Digital Pathology in Drug Development and Companion Diagnostics
5.3.1.4 Ease of Consultation Enabled By Digital Pathology
5.3.1.5 Increasing Initiatives By Governments and Industry Players
5.3.1.6 Increasing Number of Research Projects Establishing the Efficacy of Digital Pathology
5.3.2 Restraints
5.3.2.1 High Cost of Digital Pathology Systems
5.3.2.2 Regulatory Concerns
5.3.2.3 Lack of Standard Guidelines
5.3.2.4 Reluctance Among Pathologists to Adopt Advanced Technologies
5.3.3 Opportunities
5.3.3.1 Digital Pathology to Help Combat the Shortage of Pathologists
5.3.3.2 Introduction of Affordable Scanners for Private Pathology Practices
5.3.3.3 Personalized Medicine to Open Array of Opportunities
5.3.3.4 Integration of Laboratory Information Systems (LIS) and Digital Pathology Systems
5.3.3.5 Increasing Digital Pathology Initiatives in Asia
5.4 Regulatory Implications
5.4.1 Health Insurance Portability and Accountability Act (HIPAA)
5.4.2 Food and Drug Administration (FDA)
5.4.3 Clinical Laboratory Improvement Amendments (CLIA)

6 Digital Pathology Market, By Product (Page No. – 44)
6.1 Introduction
6.2 Scanners
6.3 Software
6.4 Communication Systems
6.5 Storage Systems

7 Digital Pathology Market, By Type (Page No. – 51)
7.1 Introduction
7.2 Human Digital Pathology
7.3 Animal Digital Pathology

8 Digital Pathology Market, By End User (Page No. – 55)
8.1 Introduction
8.2 Pharmaceutical & Biotechnology Companies and Cro’s
8.3 Hospitals and Reference Laboratories
8.4 Academic & Government Research Institutes

9 Digital Pathology Market, By Application (Page No. – 60)
9.1 Introduction
9.2 Teleconsultation
9.3 Disease Diagnosis
9.4 Drug Discovery
9.5 Training and Education

10 Global Digital Pathology Market, By Region (Page No. – 66)
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.1.1 Favorable Reimbursement Scenario for Digital Pathology in the U.S.
10.2.1.2 Rising Cancer Prevalence in the U.S.
10.2.1.3 De Novo Application By the FDA
10.2.2 Canada
10.2.2.1 Growing Need for Quality Cancer Diagnosis in Canada
10.2.2.2 Implementation of Favorable Initiatives By Canadian Authorities
10.3 Europe
10.3.1 EU-5
10.3.1.1 Initiatives Adopted By Nhs England Promoting the Adoption of Digital Pathology in the U.K.
10.3.1.2 Technological Developments in the U.K. Market
10.3.1.3 Organization of Digital Pathology-Related Conferences in the U.K.
10.3.1.4 Organization of Digital Pathology-Related Conferences in Germany
10.3.1.5 Successful Digital Pathology Projects in Italy
10.3.1.6 Active Involvement of Industry Players to Augment the Demand for Digital Pathology in France
10.3.1.7 Implementation of Digital Pathology-Related Projects to Drive Market Growth in Spain
10.3.2 RoE
10.3.2.1 High Cancer Prevalence to Boost Market Growth in Denmark
10.3.2.2 Norway: Conferences and Industry Collaborations in the Regional Market
10.3.2.3 Increased Investments By Government Bodies in Sweden
10.3.2.4 Digital Pathology Gaining Momentum in the Netherlands
10.4 Asia-Pacific
10.4.1 China
10.4.1.1 Industry Initiatives to Boost Digital Pathology Market in China
10.4.1.2 Favorable Initiatives for the Adoption of Telepathology in China
10.4.2 Japan
10.4.2.1 Initiatives By Nec for Cancer Diagnosis to Propel the Market in Japan
10.4.3 India
10.4.3.1 Focus of Market Players on India
10.4.4 RoAPAC
10.4.4.1 Cancer Control Initiatives in Australia
10.4.4.2 Approvals for Digital Pathology Solutions in South Korea, Partnerships Between Local and Global Players
10.5 RoW
10.5.1 Potential for the Growth of Digital Pathology in Africa
10.5.2 Increasing Focus By Industry Players and Academic Institutes on the Brazilian Market
10.5.3 Increasing Focus of Industry Players on Organic Growth Strategies in the Middle East

11 Competitive Landscape (Page No. – 105)
11.1 Overview
11.2 Competitive Situation and Trends
11.2.1 Agreements, Collaborations, and Partnerships
11.2.2 Product Launches
11.2.3 Client Acquisitions
11.2.4 Expansions
11.2.5 Acquisitions
11.2.6 Other Strategies

12 Company Profiles (Page No. – 116)
(Overview, Financial*, Products & Services, Strategy, and Developments)
12.1 Introduction
12.2 Leica Biosystems Nussloch GMBH (Subsidiary of Danaher Corp)
12.3 Ventana Medical Systems, Inc. (Member of Roche Group)
12.4 Hamamatsu Photonics K.K.
12.5 3dhistech Ltd.
12.6 Philips Healthcare
12.7 Apollo Enterprise Imaging Corp. (Formerly Apollo Pacs, Inc.)
12.8 Xifin, Inc.
12.9 Definiens AG
12.10 Visiopharm A/S
12.11 Omnyx, LLC (Venture By Ge Healthcare and UPMC)
12.12 Corista LLC

*Details Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. – 141)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Company Developments (2013–2016)
13.3.1 Leica Biosystems Nussloch GMBH (A Subsidiary of Danaher Corp)
13.3.2 Ventana Medical Systems, Inc. (A Member of Roche Group)
13.3.3 Philips Healthcare
13.3.4 Apollo Enterprise Imaging Corp. (Formerly Apollo Pacs, Inc.)
13.3.5 Definiens AG
13.3.6 Visiopharm A/S
13.3.7 Omnyx, LLC (A Venture By Ge Healthcare and UPMC)
13.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.5 Introducing RT: Real-Time Market Intelligence
13.6 Available Customizations
13.7 Related Reports